India Partially Lifts Export Ban on Potential Coronavirus Treatment After Trump’s retaliation threat. India manufactures over 70% of the World’s Hydroxychloroquine Sulphate. 50% of the USA demand for Hydroxychloroquine is fulfilled by India.
Indian pharmaceutical companies are raising monthly production of anti-malarial drug Hydroxychloroquine (HCQ) four times to 40 metric tonnes (MT) by the end of April and five to six times to over 70 metric tonnes (MT) by May 2020. The plan to step up production came after the Government of India indicated it will help countries in dire need of the drug to fight novel coronavirus. At peak capacity, companies would produce 350 million tablets of 200 mg dosage every month. India’s own requirement is unlikely to exceed 100 million tablets for which the government of India has already placed an order with Indian domestic manufacturers Zydus Cadila and Ipca Laboratories. Industry experts say 100 million tablets are good enough to treat 70 million people if required.
To continue producing at peak production capacity Indian Pharmaceuticals companies will need the intervention of the Indian government as the key active pharmaceutical ingredient (API) required to manufacture Hydroxychloroquine Sulphate is supplied by China. Production has resumed in China, but Indian Pharmaceutical companies are already staring at increased bulk prices, fluctuating freight rates, and reduced frequency of cargo flights. Indian Pharma companies are in talks with the government to airlift API to active pharmaceutical ingredient (API) from China
Meanwhile, share prices of Zydis Cadila rallied 13% while Ipca Laboratories attained a lifetime high on the close of trading at NSE (National Stock Exchange India)
With US FDA approving Anti-Malarial Drugs Chloroquine And Hydroxychloroquine For Emergency Coronavirus Treatment, Hydroxychloroquine and Azithromycin are touted to be the miracle cure.
Health Experts estimate according to one projection, between 160 million and 214 million people in the US could be infected over the course of the epidemic. That could last months or even over a year, with infections concentrated in shorter periods. Jayaprakash Muliyil is one of India’s foremost epidemiologists estimates roughly 55% of India’s population can be infected with the deadly coronavirus. To the uninitiated, India has a population of 1.3 billion.
600mg of hydroxychloroquine daily along with Azithromycin for 5 days showed encouraging results. Despite its small sample size, the survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
This report studies the global Hydroxychloroquine Sulphate market status and forecast, categorizes the global Hydroxychloroquine Sulphate market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).
The major hydroxychloroquine sulfate manufacturers covered in this report
- Sanofi
- Ipca Laboratories
- Mylan
- Vijayasri Organics Limited
- Vital Laboratories Private Limited
- Zydus Cadila
- WALLACE PHARMA
- Srini Pharmaceuticals Pvt. Ltd
- Mangalam Drugs & Organics Limited
- Laurus Labs
- TAJ Pharma
- Cinkate
- Advanz Pharma
- Shenhua Pharm
- Wuhan Wuyao Pharmaceutical
Customized separate regional or country-level for Hydroxychloroquine Sulfate reports is available for the following regions:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Singapore
- Rest of Asia-Pacific
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Rest of Europe
- Central & South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- Turkey
- Rest of Middle East & Africa
On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into
- 100mg Hydroxychloroquine Sulphate
- 200mg Hydroxychloroquine Sulphate
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
- COVID-19 / CORONA
- Discoid Lupus Erythematosus
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
Key Stakeholders
- Hydroxychloroquine Sulphate Manufacturers
- Hydroxychloroquine Sulphate Distributors/Traders/Wholesalers
- Hydroxychloroquine Sulphate Subcomponent Manufacturers
- Industry Association
- Downstream Vendors
Available Customizations
- Regional and country-level analysis of the Hydroxychloroquine Sulphate market, by end-use.
- Detailed analysis and profiles of additional market players.
Trusted Business Insights’ latest Hydroxychloroquine Sulphate Market Research Report and Azithromycin Market Sector Research Report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. We’ve been tracking the direct impact of COVID-19 on this market, as well as the indirect impact from other industries. The report will incorporate these insights. Find out who all are prepared to fulfill this massive demand and have ammunition to tackle this situation.
Request Free sample reports of this market at Hydroxychloroquine Sulphate Market Research Report and Azithromycin Market Sector Research Report
Contacts
Trusted Business Insights
Shelly Arnold
Media & Marketing Executive
Email Me For Any Clarifications
Connect on LinkedIn
Click to follow Trusted Business Insights LinkedIn for Market Data and Updates.
US: +1 646 568 9797
UK: +44 330 808 0580